Aprea Therapeutics, Inc.

As of August 12, 2025, Aprea Therapeutics, Inc. is considered overvalued and has deteriorated from a risky to a non-qualifying investment grade, with a low Price to Book Value of 0.57, an EV to EBITDA ratio of 0.63, and a significant year-to-date return of -54.41%, underperforming the S&P 500.

As of August 12, 2024, Aprea Therapeutics, Inc. is rated as "risky" and overvalued with key financial metrics indicating poor performance, including a year-to-date return of -51.37%, significantly underperforming the S&P 500's 2.44% return.

As of June 2, 2025, the market trend is mildly bearish, indicated by daily moving averages and weekly Bollinger Bands, despite some short-term strength from the MACD and KST, suggesting a cautious outlook with prevailing bearish tendencies.

As of March 2022, Aprea Therapeutics, Inc.'s management team includes Mr. Christian Schade as Chairman, President, and CEO, with Mr. John Henneman as Lead Independent Director, alongside directors Michael Kelly, Dr. Fouad Namouni, Dr. Richard Peters, and Dr. Johan Christenson.

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies that reactivate the mutant p53 tumor suppressor protein. As of March 2025, it has a market cap of $9.85 million, with no net sales and a net loss of $4 million.

As of Jun 18, Aprea Therapeutics, Inc. has a market capitalization of 9.85 million, with net sales of 1.28 million and a net profit of -14.07 million over the last four quarters. The company has shareholder's funds of 20.62 million and total assets of 23.98 million as of Dec 24.